Neurofilaments as biomarkers in neurological disorders

#	Paper	IF	Citations
920	Biomarkers for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Associated With Hexanucleotide Expansion Mutations in. **2018**, 9, 1063		20
919	A Systematic Review and Meta-Analysis of Molecular Biomarkers Associated with Early Neurological Deterioration Following Acute Stroke. **2018**, 46, 230-241		26
918	Axonal Transport, Phase-Separated Compartments, and Neuron Mechanics - A New Approach to Investigate Neurodegenerative Diseases. **2018**, 12, 358		9
917	Are neurofilaments valuable biomarkers for long-term disease prognostication in MS?. **2018**, 24, 1270-1271		7
916	Blood biomarkers in neurology: "a call to arms" for laboratory professionals. **2019**, 57, 1433-1434		2
915	Circulating neurofilament light in ischemic stroke: temporal profile and outcome prediction. **2019**, 266, 2796-2806		25
914	Plasma neurofilament light chain concentration is increased in anorexia nervosa. **2019**, 9, 180		13
913	Non-parametric combination analysis of multiple data types enables detection of novel regulatory mechanisms in T cells of multiple sclerosis patients. **2019**, 9, 11996		8
912	Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study. **2019**, 6, 1757-1770		39
911	One decade ago, one decade ahead in progressive supranuclear palsy. **2019**, 34, 1284-1293		8
910	A tear fluid proteome of Parkinson's disease. **2019**, 63, 1-2		1
909	Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches. **2019**, 57, 1556-1564		23
908	The current state of biomarker research for Friedreich's ataxia: a report from the 2018 FARA biomarker meeting. **2019**, 5, FSO398		10
907	Plasma neurofilament light chain and amyloid-𝛃 are associated with the kynurenine pathway metabolites in preclinical Alzheimer's disease. **2019**, 16, 186		28
906	Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis. **2019**, 10, 1008		28
905	Subjective Cognitive Decline and Biomarkers of Preclinical Alzheimer's Disease. **2019**, 6, 219-226		1
904	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. **2019**, 18, 1103-1111		68

903   An Update on Vitamin D and Disease Activity in Multiple Sclerosis. **2019**, 33, 1187-1199   30

902   Comparison of variables associated with cerebrospinal fluid neurofilament, total-tau, and neurogranin. **2019**, 15, 1437-1447   20

901   Impact of parturition on maternal cardiovascular and neuronal integrity in a high risk cohort - a prospective cohort study. **2019**, 19, 403   5

900   Plasma Neurofilament Light Chain in Primary Progressive Aphasia and Related Disorders: Clinical Significance and Metabolic Correlates. **2019**, 72, 773-782   7

899   Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis. **2019**, 24, 314-319   28

898   Dem MS-Phänotyp auf der Spur. **2019**, 20, 33-36   2

897   Diagnostic and Prognostic Role of Blood and Cerebrospinal Fluid and Blood Neurofilaments in Amyotrophic Lateral Sclerosis: A Review of the Literature. **2019**, 20,   20

896   Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. **2019**, 93, e1299-e1311   63

895   Editorial: Blood Tests for Alzheimer's Disease and Related Disorders. **2019**, 6, 155-156

894   Patterns of retrograde axonal degeneration in the visual system. **2019**, 142, 2775-2786   9

893   Analysis of Brain and Cerebrospinal Fluid from Mouse Models of the Three Major Forms of Neuronal Ceroid Lipofuscinosis Reveals Changes in the Lysosomal Proteome. **2019**, 18, 2244-2261   12

892   Neurofilament light chain - new potential for prediction and prognosis. *Nature Reviews Neurology*, **2019**, 15, 557   15   10

891   NfL (Neurofilament Light Chain) Levels as a Predictive Marker for Long-Term Outcome After Ischemic Stroke. **2019**, 50, 3077-3084   51

890   Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study. **2019**, 6, 453-465   75

889   The prognostic value of neurofilament levels in patients with sepsis-associated encephalopathy - A prospective, pilot observational study. **2019**, 14, e0211184   30

888   Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. **2019**, 18, 185-197   74

887   Developing therapeutic strategies to promote myelin repair in multiple sclerosis. **2019**, 19, 997-1013   11

886   Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis. **2019**, 266, 2157-2163   22

| 885 | Serum Neurofilament Light Chain Concentration Correlates with Infarct Volume but Not Prognosis in Acute Ischemic Stroke. **2019**, 28, 2242-2249 | 28 |

| 884 | Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report. **2019**, 6, 169-173 | 23 |

| 883 | Plasma and CSF neurofilament light: Relation to longitudinal neuroimaging and cognitive measures. **2019**, 93, e252-e260 | 81 |

| 882 | Blood neurofilament light as a potential endpoint in Phase 2 studies in MS. **2019**, 6, 1081-1089 | 28 |

| 881 | Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy. **2019**, 86, 322-324 | 8 |

| 880 | A frontline defense against neurodegenerative diseases:the development of early disease detection methods. **2019**, 19, 559-563 | 8 |

| 879 | The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development. **2019**, 16, 593-600 | 20 |

| 878 | Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up. **2019**, 90, 1021-1026 | 27 |

| 877 | Cerebrospinal fluid biomarkers in patients with neurological symptoms but without neurological diseases. **2019**, 140, 177-183 | 1 |

| 876 | A Serum Protein Biomarker Panel Improves Outcome Prediction in Human Traumatic Brain Injury. **2019**, 36, 2850-2862 | 78 |

| 875 | Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS. **2019**, 6, e555 | 63 |

| 874 | White matter changes in the perforant path area in patients with amyotrophic lateral sclerosis. **2019**, 45, 570-585 | 16 |

| 873 | Targeting Huntingtin Expression in Patients with Huntington's Disease. **2019**, 380, 2307-2316 | 319 |

| 872 | Neurofilament as a potential biomarker for spinal muscular atrophy. **2019**, 6, 932-944 | 76 |

| 871 | The Cerebrospinal Fluid in Multiple Sclerosis. **2019**, 10, 726 | 45 |

| 870 | Neurofilament light chain protein in neurodegenerative dementia: A systematic review and network meta-analysis. **2019**, 102, 123-138 | 32 |

| 869 | Positron Emission Tomography Molecular Imaging Biomarkers for Amyotrophic Lateral Sclerosis. **2019**, 10, 135 | 14 |

| 868 | Navigating choice in multiple sclerosis management. **2019**, 1, 5 | 4 |

849	Neurofilament Light Chain in Cerebrospinal Fluid and Blood as a Biomarker for Neurodegenerative Diseases: A Systematic Review and Meta-Analysis. **2019**, 72, 1353-1361	22
848	Quantifications of CSF Apoptotic Bodies Do Not Provide Clinical Value in Multiple Sclerosis. **2019**, 10, 1241	7
847	Molecular biomarkers in multiple sclerosis. **2019**, 16, 272	75
846	Neurofilaments in blood is a new promising preclinical biomarker for the screening of natural scrapie in sheep. **2019**, 14, e0226697	7
845	Neurofilament light is a treatment-responsive biomarker in CLN2 disease. **2019**, 6, 2437-2447	12
844	Suggestions for improving the design of clinical trials in multiple sclerosis-results of a systematic analysis of completed phase III trials. **2019**, 10, 425-436	22
843	Neurochemical biomarkers in amyotrophic lateral sclerosis. **2019**, 32, 747-757	12
842	An Update on Blood-Based Markers of Alzheimer's Disease Using the SiMoA Platform. **2019**, 8, 73-82	37
841	Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in. **2019**, 8, 37	11
840	Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate. **2019**, 14, e0226276	6
839	The relevance of buffer system ionic strength in immunoassay development. **2019**, 465, 27-30	
838	Serum neurofilament light and prediction of multiple sclerosis in clinically isolated syndrome. **2019**, 92, 313-314	0
837	Blood-based biomarkers for Alzheimer's disease-An update. **2019**, 319, 2-6	55
836	How minimal variations in neuronal cytoskeletal integrity modulate cognitive control. **2019**, 185, 129-139	17
835	A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A 'C-reactive protein' for psychiatrists and neurologists?. **2020**, 54, 57-67	18
834	Rituximab treatment for multiple sclerosis. **2020**, 26, 137-152	28
833	Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis. **2020**, 26, 659-667	17
832	Serum NfL levels should be used to monitor multiple sclerosis evolution - Yes. **2020**, 26, 17-19	6

831 — Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders. **2020**, 267, 162-167 — 36

830 — Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study. **2020**, 26, 1670-1681 — 33

829 — Elevated CSF neurofilament light chain concentration in a patient with facial onset sensory and motor neuronopathy. **2020**, 41, 217-219 — 1

828 — Neurofilament Light Chain as a Biomarker, and Correlation with Magnetic Resonance Imaging in Diagnosis of CNS-Related Disorders. **2020**, 57, 469-491 — 21

827 — Internationale Brain Health Initiative und Multiple Sklerose. **2020**, 3, 107-115 — 2

826 — Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis. **2020**, 77, 58-64 — 59

825 — Serum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis. **2020**, 26, 1682-1690 — 14

824 — Early Intrathecal T Helper 17.1 Cell Activity in Huntington Disease. **2020**, 87, 246-255 — 10

823 — Plasma neurofilament light in progressive multiple sclerosis. **2020**, 141, 14-15 — 1

822 — Vitamin D supplementation and neurofilament light chain in multiple sclerosis. **2020**, 141, 77-80 — 11

821 — Confounding effect of blood volume and body mass index on blood neurofilament light chain levels. **2020**, 7, 139-143 — 49

820 — Intrathecal nusinersen treatment after ventriculo-peritoneal shunt placement: A case report focusing on the neurofilament light chain in cerebrospinal fluid. **2020**, 42, 311-314 — 6

819 — Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy. **2020**, 27, 97-102 — 14

818 — Protein aggregate formation permits millennium-old brain preservation. **2020**, 17, 20190775 — 4

817 — Plasma biomarkers of astrocytic and neuronal dysfunction in early- and late-onset Alzheimer's disease. **2020**, 16, 681-695 — 56

816 — Association of Cognitive and Behavioral Features Between Adults With Tuberous Sclerosis and Frontotemporal Dementia. **2020**, 77, 358-366 — 7

815 — CSF or serum neurofilament light added to Synuclein panel discriminates Parkinson's from controls. **2020**, 35, 288-295 — 28

814 — Active poly-GA vaccination prevents microglia activation and motor deficits in a C9orf72 mouse model. **2020**, 12, e10919 — 24

| 813 | Advances and considerations in AD tau-targeted immunotherapy. **2020**, 134, 104707 | 34 |

| 812 | Postoperative delirium is associated with increased plasma neurofilament light. **2020**, 143, 47-54 | 42 |

| 811 | Serum neurofilament light chain (NFL) remains unchanged during electroconvulsive therapy. **2020**, 21, 148-154 | 9 |

| 810 | Plasma Neurofilament Light Chain Is Associated with Poor Functional Outcome and Mortality Rate After Spontaneous Subarachnoid Hemorrhage. **2020**, 11, 671-677 | 11 |

| 809 | Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment. **2020**, 26, 23-37 | 32 |

| 808 | Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence. **2020**, 91, 9-14 | 10 |

| 807 | Neurofilament Light Chain as A Biomarker for Brain Metastases. **2020**, 12, | 10 |

| 806 | Biomarkers of neuronal damage in saturation diving-a controlled observational study. **2020**, 120, 2773-2784 | 2 |

| 805 | Serum neurofilament light chain: No clear relation to cognition and neuropsychiatric symptoms in stable MS. **2020**, 7, | 10 |

| 804 | Amyloid-PET and F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. **2020**, 19, 951-962 | 95 |

| 803 | Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers. **2020**, 15, 58 | 25 |

| 802 | Evaluation of neurofilament light chain in the cerebrospinal fluid and blood as a biomarker for neuronal damage in experimental pneumococcal meningitis. **2020**, 17, 293 | 6 |

| 801 | Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. **2020**, 31, 1306-1319 | 62 |

| 800 | Plasma Aβand neurofilament light chain are associated with cognitive and physical function decline in non-dementia older adults. **2020**, 12, 128 | 7 |

| 799 | Plasma NfL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy. **2020**, 7, 2127-2136 | 7 |

| 798 | Thirty years after anorexia nervosa onset, serum neurofilament light chain protein concentration indicates neuronal injury. **2021**, 30, 1907-1915 | 4 |

| 797 | Recent Advances in Blood-Based Biomarkers of Remote Combat-Related Traumatic Brain Injury. **2020**, 20, 54 | 1 |

| 796 | Distinguishing physiological versus pathological serum NfL levels in multiple sclerosis will require serial measurements. **2020**, 46, 102477 | |

777	Advantages and Pitfalls in Fluid Biomarkers for Diagnosis of Alzheimer's Disease. **2020**, 10,	4
776	Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer's disease. **2020**, 95, 143-153	17
775	Circulating Neurofilament Light Chain Is Associated With Survival After Pediatric Cardiac Arrest. **2020**, 21, 656-661	4
774	Neurofilament light chain as biomarker in idiopathic intracranial hypertension. **2020**, 40, 1346-1354	1
773	The Identification of Novel Biomarkers Is Required to Improve Adult SMA Patient Stratification, Diagnosis and Treatment. **2020**, 10,	8
772	Tracking the potential involvement of metabolic disease in Alzheimer's disease-Biomarkers and beyond. **2020**, 154, 51-77	3
771	Large-scale informatic analysis to algorithmically identify blood biomarkers of neurological damage. **2020**, 117, 20764-20775	5
770	Comparing progression biomarkers in clinical trials of early Alzheimer's disease. **2020**, 7, 1661-1673	14
769	NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS. **2020**, 46, 102463	6
768	A conscious rethink: Why is brain tissue commonly preserved in the archaeological record? Commentary on: Petrone P, Pucci P, Niola M, et al. Heat-induced brain vitrification from the Vesuvius eruption in C.E. 79. N Engl J Med 2020;382:383-4. DOI: 10.1056/NEJMc1909867. **2020**, 6, 87-95	0
767	Serum Neurofilament Light Chain Levels are Associated with Lower Thalamic Perfusion in Multiple Sclerosis. **2020**, 10,	1
766	CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment. **2020**, 41, 1023-1037	15
765	Unraveling Pathophysiological Mechanisms of Parkinson's Disease: Contribution of CSF Biomarkers. **2020**, 15, 1177271920964077	3
764	A review of novel biomarkers and imaging techniques for assessing the severity of chemotherapy-induced peripheral neuropathy. **2020**, 16, 1147-1158	2
763	Longitudinal Serum Neurofilament Levels of Multiple Sclerosis Patients Before and After Treatment with First-Line Immunomodulatory Therapies. **2020**, 8,	5
762	Why Cognitive-Cognitive Dual-Task Testing Assessment Should Be Implemented in Studies on Multiple Sclerosis and in Regular Clinical Practice. **2020**, 11, 905	1
761	Neurofilament light chain level in traumatic brain injury: A system review and meta-analysis. **2020**, 99, e22363	16
760	Genomic, proteomic, and systems biology approaches in biomarker discovery for multiple sclerosis. **2020**, 358, 104219	8

759	Elevated plasma neurofilament light in aging reflects brain white-matter alterations but does not predict cognitive decline or Alzheimer's disease. **2020**, 12, e12050	8
758	Dramatic clinical response to ultra-high dose IVIg in otherwise treatment resistant inflammatory neuropathies. **2020**, 1-10	3
757	Cerebrospinal fluid and blood levels of neurofilament light chain in Parkinson disease: A protocol for systematic review and meta-analysis. **2020**, 99, e21458	2
756	The effect of lumbar puncture on the neurodegeneration biomarker neurofilament light in macaque monkeys. **2020**, 12, e12069	4
755	Neurofilament light in blood - What more is needed for clinical implementation in multiple sclerosis?. **2020**, 57, 102826	
754	Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Sensitivity, Specificity and Potential for Clinical Use. **2020**, 10,	10
753	Fluid Biomarkers for Synaptic Dysfunction and Loss. **2020**, 15, 1177271920950319	23
752	Is CSF neurofilament light chain measurement relevant for MS?. **2020**, 7,	1
751	Association of serum neurofilament light and disease severity in patients with spinocerebellar ataxia type 3. **2020**, 95, e2977-e2987	5
750	Long-term prognostic value of longitudinal measurements of blood neurofilament levels. **2020**, 7,	11
749	Plasma NT1 Tau is a Specific and Early Marker of Alzheimer's Disease. **2020**, 88, 878-892	8
748	Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring. **2021**, 27, 1497-1505	9
747	Renal function is associated with blood neurofilament light chain level in older adults. **2020**, 10, 20350	26
746	Serum neurofilament light chain withstands delayed freezing and repeated thawing. **2020**, 10, 19982	12
745	Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. **2020**, 11, 6252	15
744	Biomarkers: Our Path Towards a Cure for Alzheimer Disease. **2020**, 15, 1177271920976367	9
743	E.U. paediatric MOG consortium consensus: Part 3 - Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. **2020**, 29, 22-31	11
742	Elevated Levels of Serum Neurofilament Light Chain Associated with Cognitive Impairment in Vascular Dementia. **2020**, 2020, 6612871	3

741	Blood neurofilament light: a critical review of its application to neurologic disease. **2020**, 7, 2508-2523	39
740	Serum Neurofilament Levels in Children With Febrile Seizures and in Controls. **2020**, 14, 579958	8
739	Diagnosis of ischemic stroke using circulating levels of brain-specific proteins measured via high-sensitivity digital ELISA. **2020**, 1739, 146861	8
738	Shared proteomic effects of cerebral atherosclerosis and Alzheimer's disease on the human brain. **2020**, 23, 696-700	33
737	Clinical, Radiological, and Laboratory Features of Spinal Cord Involvement in Primary Sjögren's Syndrome. **2020**, 9,	2
736	Longitudinal Development of Peripapillary Hyper-Reflective Ovoid Masslike Structures Suggests a Novel Pathological Pathway in Multiple Sclerosis. **2020**, 88, 309-319	5
735	Functional Characterization of Neurofilament Light Splicing and Misbalance in Zebrafish. **2020**, 9,	1
734	Cerebrospinal Fluid Biomarkers to Differentiate Idiopathic Normal Pressure Hydrocephalus from Subcortical Ischemic Vascular Disease. **2020**, 75, 937-947	4
733	Plasma Neurofilament Light and Longitudinal Progression of White Matter Hyperintensity in Elderly Persons Without Dementia. **2020**, 75, 729-737	7
732	Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. **2020**, 56, 102807	30
731	Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis. **2020**, 7,	14
730	Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy. **2020**, 10, 7995	11
729	Neurofilaments: neurobiological foundations for biomarker applications. **2020**, 143, 1975-1998	56
728	Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study. **2020**, 19, 513-521	53
727	The relationship between ANT1 and NFL with autophagy and mitophagy markers in patients with multiple sclerosis. **2020**, 78, 307-312	6
726	Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis. **2020**, 94, e2457-e2467	29
725	Serum neurofilament light chain in FTLD: association with C9orf72, clinical phenotype, and prognosis. **2020**, 7, 903-910	8
724	Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis. **2020**, 7, 945-955	15

723   Clues to prognosis in multiple sclerosis found in the blood. *Nature Reviews Neurology*, **2020**, 16, 349   15

722   Development of an assay of plasma neurofilament light chain utilizing immunomagnetic reduction technology. **2020**, 15, e0234519   3

721   Further understanding the connection between Alzheimer's disease and Down syndrome. **2020**, 16, 1065-1077   32

720   Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases. **2020**, 7, 992-1001   10

719   Stress cardiomyopathy associated with the first manifestation of multiple sclerosis: a case report. **2020**, 20, 227   2

718   Combining biomarkers to profile multiple sclerosis patients. *Nature Reviews Neurology*, **2020**, 16, 463-464   0

717   Cerebrospinal Fluid 7-Ketocholesterol Level is Associated with Amyloid-42 and White Matter Microstructure in Cognitively Healthy Adults. **2020**, 76, 643-656   2

716   Serum neurofilament light chain studies in neurological disorders, hints for interpretation. **2020**, 416, 116986   8

715   Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease. **2020**, 15, 33   16

714   Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. **2020**, 142, 104960   15

713   The conserved DNMT1-dependent methylation regions in human cells are vulnerable to neurotoxicant rotenone exposure. **2020**, 13, 17   4

712   Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barr⬚ syndrome. **2020**, 17, 86   23

711   Neurofilaments in disease: what do we know?. **2020**, 61, 105-115   17

710   Imaging of Neuromyelitis Optica Spectrum Disorders. **2020**, 41, 319-331   0

709   Next-Generation Neuroimmunology: New Technologies to Understand Central Nervous System Autoimmunity. **2020**, 41, 341-354   7

708   Degree of genetic liability for Alzheimer's disease associated with specific proteomic profiles in cerebrospinal fluid. **2020**, 93, 144.e1-144.e15   6

707   Diagnostic utility of fluid biomarkers in multiple system atrophy: a systematic review and meta-analysis. **2021**, 268, 2703-2712   9

706   Elevated serum neurofilament light chain in children autism spectrum disorder: A case control study. **2020**, 80, 87-92   3

705	Phenotypic bases of NOTCH2NLC GGC expansion positive neuronal intranuclear inclusion disease in a Southeast Asian cohort. **2020**, 98, 274-281	10
704	Increased plasma neurofilament light chain levels in patients with type-1 diabetes with impaired awareness of hypoglycemia. **2020**, 8,	3
703	Neurofilament light as a biomarker in traumatic brain injury. **2020**, 95, e610-e622	41
702	Nervous system: subclinical target of SARS-CoV-2 infection. **2020**, 91, 1010-1012	6
701	Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers. **2020**, 9, 27	10
700	Progress in the diagnosis of traumatic brain injury. **2020**, 95, 235-236	2
699	Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19. **2020**, 267, 3476-3478	36
698	Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice. **2020**, 12, e11803	20
697	Neurofilament Light Chain-It Is Not Just About Concussions. **2020**, 21, 685-686	
696	Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients. **2020**, 24, 3034-3039	21
695	Neurofilament light and tau in serum after head-impact exposure in soccer. **2020**, 34, 602-609	8
694	Axons Matter: The Promise of Treating Neurodegenerative Disorders by Targeting SARM1-Mediated Axonal Degeneration. **2020**, 41, 281-293	38
693	Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. **2020**, 26, 387-397	236
692	The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. **2020**, 20, 421-441	19
691	Short Keynote Paper: Single Molecule Detection of Protein Biomarkers to Define the Continuum From Health to Disease. **2020**, 24, 1864-1868	3
690	cADPR is a gene dosage-sensitive biomarker of SARM1 activity in healthy, compromised, and degenerating axons. **2020**, 329, 113252	34
689	Structural Variants May Be a Source of Missing Heritability in sALS. **2020**, 14, 47	13
688	Evaluation of single molecule array digital immunoassay technology to quantitate neurofilament light chain. **2020**, 12, 221-229	1

687   Diagnostic and prognostic values of PBMC proteins in amyotrophic lateral sclerosis. **2020**, 139, 104815   8

686   Reference interval and preanalytical properties of serum neurofilament light chain in Scandinavian adults. **2020**, 80, 291-295   31

685   Accelerated neuronal and synaptic maturation by BrainPhys medium increases Aβ secretion and alters Aβ peptide ratios from iPSC-derived cortical neurons. **2020**, 10, 601   11

684   Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course-a joint PhD student course at University College London and University of Gothenburg. **2020**, 12, 20   13

683   Advances in oral immunomodulating therapies in relapsing multiple sclerosis. **2020**, 19, 336-347   54

682   Blood neurofilament light levels segregate treatment effects in multiple sclerosis. **2020**, 94, e1201-e1212   46

681   Feast or famine in multiple sclerosis therapeutics. **2020**, 19, 196-197   3

680   Neurofilaments: The C-Reactive Protein of Neurology. **2020**, 10,   19

679   The potential of neurofilaments analysis using dry-blood and plasma spots. **2020**, 10, 97   4

678   Trem2 Deletion Reduces Late-Stage Amyloid Plaque Accumulation, Elevates the Aβ42:Aβ40 Ratio, and Exacerbates Axonal Dystrophy and Dendritic Spine Loss in the PS2APP Alzheimer's Mouse Model. **2020**, 40, 1956-1974   55

677   Plasma Neurofilament Light Chain May Be a Biomarker for the Inverse Association Between Cancers and Neurodegenerative Diseases. **2020**, 12, 10   7

676   Behavioral abnormalities and phosphorylation deficits of extracellular signal-regulated kinases 1 and 2 in rat offspring of the maternal immune activation model. **2020**, 217, 112805   1

675   CHIT1 at Diagnosis Reflects Long-Term Multiple Sclerosis Disease Activity. **2020**, 87, 633-645   10

674   University College London/University of Gothenburg PhD course "Biomarkers in neurodegenerative diseases" 2019-course organisation. **2020**, 12, 18

673   Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. **2020**, 91, 612-621   22

672   Current state-of-art of the application of serum neurofilaments in multiple sclerosis diagnosis and monitoring. **2020**, 20, 747-769   6

671   Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity. **2020**, 94, 2517-2522   20

670   Circulating Brain Injury Exosomal Proteins following Moderate-To-Severe Traumatic Brain Injury: Temporal Profile, Outcome Prediction and Therapy Implications. **2020**, 9,   26

669	Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis. **2020**, 7, 799-807	6
668	Association of postoperative covert stroke and cognitive dysfunction among elderly patients undergoing non-cardiac surgery: protocol for a prospective cohort study (PRECISION study). **2020**, 10, e034657	4
667	Anti-neurofilament antibodies and neurodegeneration: Markers and generators. **2020**, 344, 577248	2
666	Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease. **2020**, 74, 43-49	21
665	Cerebrospinal fluid MFG-E8 as a promising biomarker of amyotrophic lateral sclerosis. **2020**, 41, 2915-2920	6
664	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. *Nature Reviews Neurology*, **2020**, 16, 265-284	15	53
663	Biomarker profiling beyond amyloid and tau: cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults. **2020**, 93, 1-15	6
662	New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis. **2020**, 29, 443-459	13
661	Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis. **2021**, 27, 220-231	24
660	Association of intrathecal pleocytosis and IgG synthesis with axonal damage in early MS. **2020**, 7,	9
659	Monitoring of radiologic disease activity by serum neurofilaments in MS. **2020**, 7,	16
658	The role of neurofilament light chain in frontotemporal dementia: a meta-analysis. **2021**, 33, 869-881	8
657	Biomarkers for Alzheimer's disease-preparing for a new era of disease-modifying therapies. **2021**, 26, 296-308	85
656	Molecular Biomarkers for Spinal Muscular Atrophy: A Systematic Review. **2021**, 11, e524-e536	0
655	Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patients. **2020**,	12
654	Longitudinal measurement of cerebrospinal fluid neurofilament light in anti-N-methyl-D-aspartate receptor encephalitis. **2021**, 28, 1401-1405	5
653	Immunohistochemical Markers in the Diagnosis of Calcifying Pseudoneoplasm of the Neuraxis. **2021**, 48, 259-266	2
652	Plasma lipids are associated with white matter microstructural changes and axonal degeneration. **2021**, 15, 1043-1057	6

633	Implications of extreme serum neurofilament light chain levels for the management of patients with relapsing multiple sclerosis. **2021**, 14, 17562864211001977		0
632	Phosphorylated Neurofilament Heavy Chain (pNFH) in Clinically Isolated Syndrome and Multiple Sclerosis.. **2021**, 58, 255-256		
631	Standardization and digitization of clinical data in multiple sclerosis. *Nature Reviews Neurology*, **2021**, 17, 119-125	15	3
630	Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019. **2021**, 89, 610-616		29
629	Gene-Targeting Therapeutics for Neurological Disease: Lessons Learned from Spinal Muscular Atrophy. **2021**, 72, 1-14		5
628	Progressive Supranuclear Palsy and Corticobasal Degeneration. **2021**, 1281, 151-176		2
627	Neuronal structure in aging. **2021**, 53-64		
626	microRNAs as Early Biomarkers of Alzheimer's Disease: A Synaptic Perspective. **2021**, 10,		13
625	Depression and anxiety disorders in patients with multiple sclerosis: association with neurodegeneration and neurofilaments. **2021**, 54, e10428		2
624	Serum neurofilament levels reflect outer retinal layer changes in multiple sclerosis. **2021**, 14, 17562864211003478		4
623	Parkinson's disease with restless legs syndrome-an in vivo corneal confocal microscopy study. **2021**, 7, 4		6
622	Translational Value of CSF and Blood Markers of Autoimmunity and Neurodegeneration. **2021**, 77-86		
621	Characterization of the Expression of Vacuolar Protein Sorting 11 (Vps11) in Mammalian Oligodendrocytes. **2021**, 13, 17590914211009851		
620	Impaired prenatal motor axon development necessitates early therapeutic intervention in severe SMA. **2021**, 13,		19
619	Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease. **2021**, 10, e1316		3
618	Serum biomarkers of cerebral cellular stress after self-limiting tonic clonic seizures: An exploratory study. **2021**, 85, 1-5		7
617	The dazzling rise of neurofilaments: Physiological functions and roles as biomarkers. **2021**, 68, 181-191		8
616	Towards blood biomarkers for stroke patients. **2021**, 41, 914-916		0

615	Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics. **2021**, 16, 10	35
614	Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis. **2021**, 27, 2014-2022	7
613	Plasma Neurofilament Light Chain as a Predictive Biomarker for Post-stroke Cognitive Impairment: A Prospective Cohort Study. **2021**, 13, 631738	3
612	Neurofilament light chain levels reflect outcome in a patient with glutamic acid decarboxylase 65 antibody-positive autoimmune encephalitis under immune checkpoint inhibitor therapy. **2021**, 28, 1086-1089	1
611	Associations between plasma neurofilament light, in vivo brain pathology, and cognition in non-demented individuals with autosomal-dominant Alzheimer's disease. **2021**, 17, 813-821	4
610	A neuronal blood marker is associated with mortality in old age. **2021**, 1, 218-225	10
609	Serum levels of neurofilament light chain, neuron-specific enolase and S100 calcium-binding protein B during acute bacterial meningitis: a prospective cohort study. **2021**, 53, 409-419	2
608	Early life serum neurofilament dynamics predict neurodevelopmental outcome of preterm infants. **2021**, 268, 2570-2577	3
607	Differential longitudinal changes of neuronal and glial damage markers in anorexia nervosa after partial weight restoration. **2021**, 11, 86	3
606	CSF and Blood Neurofilament Levels in Athletes Participating in Physical Contact Sports: A Systematic Review. **2021**, 96, 705-715	3
605	Serum neurofilament light and tau as prognostic markers for all-cause mortality in the elderly general population-an analysis from the MEMO study. **2021**, 19, 38	6
604	Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. **2021**, 2, e87-e95	21
603	Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. **2021**, 11, e02084	7
602	Elevated Neurofilament Light Chain in Cerebrospinal Fluid and Plasma Reflect Inflammatory MRI Activity in Neurosarcoidosis. **2021**, 11,	4
601	Serum Neurofilament Light Chain Measurement in MS: Hurdles to Clinical Translation. **2021**, 15, 654942	11
600	Biomarkers and the Role of ßSynuclein in Parkinson's Disease. **2021**, 13, 645996	5
599	Neurological symptoms and blood neurofilament light levels. **2021**, 144, 13-20	4
598	Biological variation of serum neurofilament light chain. **2021**,	1

597	Targeting Lyn Kinase in Chorea-Acanthocytosis: A Translational Treatment Approach in an Ultra-Rare Disease.	1
596	Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. **2021**, 89, 895-910	23
595	Neurofilament light chain as a potential biomarker for monitoring neurodegeneration in X-linked adrenoleukodystrophy. **2021**, 12, 1816	7
594	The fluid biomarkers of Alzheimer's disease. **2021**, 7, 1-16	
593	Electrochemical immunoplatform to unravel neurodegeneration and Alzheimer's disease through the determination of neurofilament light protein. **2021**, 371, 137815	6
592	Association of Plasma Neurofilament Light With Small Vessel Disease Burden in Nondemented Elderly: A Longitudinal Study. **2021**, 52, 896-904	8
591	Genetic inactivation of RIP1 kinase activity in rats protects against ischemic brain injury. **2021**, 12, 379	0
590	Metabolic and muscle-derived serum biomarkers define CHCHD10-linked late-onset spinal muscular atrophy.	
589	Neurofilament Light Chain Is a Biomarker of Neurodegeneration in Ataxia Telangiectasia. **2021**, 1	3
588	Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis. **2021**, 12, 650530	2
587	Blood molecular biomarkers for chemotherapy-induced peripheral neuropathy: From preclinical models to clinical practice. **2021**, 749, 135739	5
586	Diagnose it yourself: will there be a home test kit for Alzheimer's disease?. **2021**, 11, 167-176	
585	Neurofilament light chain as a marker for cortical atrophy in multiple sclerosis without radiological signs of disease activity. **2021**, 290, 473-476	0
584	No neurochemical evidence of neuronal injury or glial activation in children with Paediatric Acute-onset Neuropsychiatric Syndrome. An explorative pilot study. **2021**, 22, 800-804	0
583	Tissue Transglutaminase Expression Associates With Progression of Multiple Sclerosis. **2021**, 8,	2
582	The Evolution of Neurofilament Light Chain in Multiple Sclerosis. **2021**, 15, 642384	11
581	Serum neurofilament light chain (sNfL) values in a large cross-sectional population of children with asymptomatic to moderate COVID-19. **2021**, 268, 3969-3974	3
580	Neurofilaments as Emerging Biomarkers of Neuroaxonal Damage to Differentiate Behavioral Frontotemporal Dementia from Primary Psychiatric Disorders: A Systematic Review. **2021**, 11,	1

579	Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab. **2021**, 8,	2
578	Neurofilament light chain as novel blood biomarker of disturbed neuroaxonal integrity in patients with ketamine dependence. **2021**, 22, 713-721	4
577	Biomarkers in neurological disorders: a fast-growing market. **2021**, 3, fcab086	1
576	Calcifying Pseudoneoplasm of the Neuraxis: From Pathogenesis to Diagnostic and Therapeutic Considerations. **2021**, 148, 165-176	1
575	Associations Between Physical Activity, Blood-Based Biomarkers of Neurodegeneration, and Cognition in Healthy Older Adults: The MAPT Study. **2021**, 76, 1382-1390	3
574	Serum Levels of Clusterin, PKR, and RAGE Correlate with Amyloid Burden in Alzheimer's Disease. **2021**, 80, 1067-1077	4
573	A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. **2021**, 13, 80	92
572	Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study. **2021**, 85, 11-16	5
571	CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event. **2021**, 13524585211010082	1
570	Cerebrospinal Fluid Neurofilament Light Chain (NfL) Predicts Disease Aggressiveness in Amyotrophic Lateral Sclerosis: An Application of the D50 Disease Progression Model. **2021**, 15, 651651	3
569	Plasma neurofilament light chain levels predict improvement in late phase after stroke. **2021**, 28, 2218-2228	1
568	Evaluation of Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Screening and Monitoring Biomarkers for Brain Metastases. **2021**, 13,	0
567	Circulating hsa-miR-323b-3p in Huntington's Disease: A Pilot Study. **2021**, 12, 657973	2
566	Ultrasensitive immunoassay allows measurement of serum neurofilament heavy in multiple sclerosis. **2021**, 50, 102840	1
565	Relationship Between General Cognition, Visual Assessed Cortical Atrophy, and Cerebrospinal Fluid Biomarkers in Alzheimer's Disease: A Cross-Sectional Study from a Chinese PUMCH Cohort. **2021**, 82, 205-214	0
564	The Cytoskeletal Elements MAP2 and NF-L Show Substantial Alterations in Different Stroke Models While Elevated Serum Levels Highlight Especially MAP2 as a Sensitive Biomarker in Stroke Patients. **2021**, 58, 4051-4069	6
563	Can serum glial fibrillary acidic protein (GFAP) solve the longstanding problem of diagnosis and monitoring progressive multiple sclerosis. **2021**, 50, 102931	1
562	Circulating Neurofilament Light Predicts Cognitive Decline in Patients With Post-stroke Subjective Cognitive Impairment. **2021**, 13, 665981	4

561	Saliva Neurofilament Light Chain Is Not a Diagnostic Biomarker for Neurodegeneration in a Mixed Memory Clinic Population. **2021**, 13, 659898	3
560	Targeting Lyn Kinase in Chorea-Acanthocytosis: A Translational Treatment Approach in a Rare Disease. **2021**, 11,	3
559	Serum Neurofilament Light is Elevated in COVID-19 Positive Adults in the ICU and is Associated with Co-Morbid Cardiovascular Disease, Neurological Complications, and Acuity of Illness.	
558	Seven day pre-analytical stability of serum and plasma neurofilament light chain. **2021**, 11, 11034	6
557	Kynurenines and Neurofilament Light Chain in Multiple Sclerosis. **2021**, 15, 658202	1
556	Serum Short-Chain Fatty Acids and Associations With Inflammation in Newly Diagnosed Patients With Multiple Sclerosis and Healthy Controls. **2021**, 12, 661493	11
555	Biomarkers of Cerebral Injury for Prediction of Postoperative Cognitive Dysfunction in Patients Undergoing Cardiac Surgery. **2021**,	4
554	A neurologist's perspective on serum neurofilament light in the memory clinic: a prospective implementation study. **2021**, 13, 101	5
553	Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. **2021**, 18, 105	12
552	NfL levels predominantly increase at disease onset in MOG-Abs-associated disorders. **2021**, 50, 102833	8
551	Serum and cerebrospinal fluid phosphorylated neurofilament heavy protein concentrations in equine neurodegenerative diseases. **2021**,	3
550	Biomarkers and Their Implications in Alzheimer's Disease: A Literature Review. **2021**, 000, 000-000	1
549	Neurofilament light: a narrative review on biomarker utility. **2021**, 10, 46	1
548	Neurofilament light chain in patients with a concussion or head impacts: a systematic review and meta-analysis. **2021**, 1	4
547	Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia. **2021**, 109, 1657-1674.e7	34
546	Peripheral neuropathy linked mRNA export factor GANP reshapes gene regulation in human motor neurons.	
545	Spinocerebellar ataxia clinical trials: opportunities and challenges. **2021**, 8, 1543-1556	7
544	Neurofilament Light Chain (NfL) in Blood-A Biomarker Predicting Unfavourable Outcome in the Acute Phase and Improvement in the Late Phase after Stroke. **2021**, 10,	2

525	Changes in telomere length and serum neurofilament light chain levels in female patients with chronic insomnia disorder. **2021**,	1
524	Early rise in brain damage markers and high ICOS expression in CD4+ and CD8+ T cells during checkpoint inhibitor-induced encephalomyelitis. **2021**, 9,	1
523	14-Year Changes in Plasma Neurofilament Levels Among Men: A Pilot Study. **2021**, 8, 621-624	
522	Absolute serum neurofilament light chain levels and its early kinetics predict brain injury after out-of-hospital cardiac arrest. **2021**, 1	0
521	Comparative diagnosis interest of NfL and pNfH in CSF and plasma in a context of FTD-ALS spectrum. **2021**, 1	0
520	Circulating brain injury biomarkers increase after endoscopic surgery for pituitary tumors. **2021**, 89, 113-121	1
519	Serum neurofilament light chain or glial fibrillary acidic protein in the diagnosis and prognosis of brain metastases. **2021**, 1	1
518	Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. **2021**, 12, 4304	11
517	Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview. **2021**, 25, 563-576	1
516	Cerebrospinal fluid neurofilament light levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment.. **2021**, 10, 614	0
515	Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity. **2021**, 11,	1
514	Interleukin-1 receptor antagonist: An exploratory plasma biomarker that correlates with disability and provides pathophysiological insights in relapsing-remitting multiple sclerosis. **2021**, 52, 103006	1
513	Therapeutic Response and Possible Biomarkers in Acute Attacks of Neuromyelitis Optica Spectrum Disorders: A Prospective Observational Study. **2021**, 12, 720907	0
512	Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study. **2021**, 13524585211039104	1
511	Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. **2021**, 70, 103512	23
510	Clinical and Paraclinical Biomarkers and the Hitches to Assess Conversion to Secondary Progressive Multiple Sclerosis: A Systematic Review. **2021**, 12, 666868	3
509	Neurological symptoms and axonal damage in COVID-19 survivors: are there sequelae?. **2021**, 69, 553-557	1
508	Combination of Plasma Neurofilament Light Chain and Mini-Mental State Examination Score Predicts Progression from Mild Cognitive Impairment to Alzheimer's Disease within 5 Years. **2021**, 82, 951-964	1

507	Prediagnostic Neurofilament Light Chain Levels in Amyotrophic Lateral Sclerosis. **2021**,	2
506	Extracellular fluid, cerebrospinal fluid and plasma biomarkers of axonal and neuronal injury following intracerebral hemorrhage. **2021**, 11, 16950	0
505	Tetravalent Influenza Vaccine Is Not Associated With Neuroaxonal Damage in Multiple Sclerosis Patients. **2021**, 12, 718895	
504	Sustained Axonal Degeneration in Prolonged Disorders of Consciousness. **2021**, 11,	1
503	Altered neuroaxonal integrity in schizophrenia and major depressive disorder assessed with neurofilament light chain in serum. **2021**, 140, 141-148	8
502	Response to mitogen-activated protein kinase inhibition of neurodegeneration in Langerhans cell histiocytosis monitored by cerebrospinal fluid neurofilament light as a biomarker: a pilot study. **2021**,	0
501	Outcome measures assisting treatment optimization in multiple sclerosis. **2021**, 1	0
500	Plasma neurofilament light as a potential biomarker for cognitive decline in a longitudinal study of middle-aged urban adults. **2021**, 11, 436	1
499	Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS. **2021**,	9
498	Reference values for plasma neurofilament light chain in healthy Chinese children. **2022**, 60, e10-e12	0
497	Plasma NfL levels and longitudinal change rates in and -associated diseases: from tailored references to clinical applications. **2021**, 92, 1278-1288	2
496	Neurofilament light chain and glial fibrillary acidic protein levels in metachromatic leukodystrophy. **2021**,	2
495	Serum markers of brain injury can predict good neurological outcome after out-of-hospital cardiac arrest. **2021**, 47, 984-994	10
494	Disease biomarkers in multiple sclerosis: current serum neurofilament light chain perspectives. **2021**, 11, 329-340	1
493	Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. **2021**, 20, 605-614	9
492	Serum Neurofilament Dynamics Predicts Cognitive Progression in de novo Parkinson's Disease. **2021**, 11, 1117-1127	1
491	Assessment of diagnostic potential of some circulating microRNAs in Amyotrophic Lateral Sclerosis Patients, an Egyptian study. **2021**, 208, 106883	1
490	Charcot-Marie-Tooth disease type 2CC due to variants causes a progressive, non-length-dependent, motor-predominant phenotype. **2021**,	0

489	Potential markers for sample size estimations in hereditary spastic paraplegia type 5. **2021**, 16, 391	0
488	Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis. **2021**, 97, e1898-e1905	12
487	Neurofilament Light Chain and Intermediate HTT Alleles as Combined Biomarkers in Italian ALS Patients. **2021**, 15, 695049	
486	Serum phosphorylated neurofilament heavy chain as a diagnostic biomarker for progressive myelomalacia in dogs with thoracolumbar intervertebral disc herniation. **2021**, 35, 2366-2373	1
485	Identification of the Prodromal Symptoms and Pre-Ataxic Stage in Cerebellar Disorders: The Next Challenge. **2021**, 18,	1
484	CSF Chitinase 3-Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis. **2021**, 8,	2
483	Serum Neurofilament Light: a Potential Diagnostic and Prognostic Biomarker in Obstetric Posterior Reversible Encephalopathy Syndrome. **2021**, 58, 6460-6470	2
482	Blood biomarkers for mild traumatic brain injury: a selective review of unresolved issues. **2021**, 9, 70	7
481	Blood Neurofilament Light Chain in Genetic Ataxia: A Meta-Analysis. **2021**,	1
480	Plasma neurofilament light chain level predicts outcomes in stroke patients receiving endovascular thrombectomy. **2021**, 18, 195	2
479	Microstructure-Weighted Connectomics in Multiple Sclerosis. **2021**,	1
478	Neurofilament Proteins as Biomarkers to Monitor Neurological Diseases and the Efficacy of Therapies. **2021**, 15, 689938	10
477	The blood biomarkers puzzle - A review of protein biomarkers in neurodegenerative diseases. **2021**, 361, 109281	4
476	Calprotectin in Chronic Inflammatory Demyelinating Polyneuropathy and Variants-A Potential Novel Biomarker of Disease Activity. **2021**, 12, 723009	2
475	MFN2 Deficiency Impairs Mitochondrial Transport and Downregulates Motor Protein Expression in Human Spinal Motor Neurons. **2021**, 14, 727552	1
474	Genetic Association Between Schizophrenia and Cortical Brain Surface Area and Thickness. **2021**, 78, 1020-1030	4
473	Serum neurofilament light chain levels in healthy individuals: A proposal of cut-off values for use in multiple sclerosis clinical practice. **2021**, 54, 103090	2
472	Sequencing of neurofilament genes identified NEFH Ser787Arg as a novel risk variant of sporadic amyotrophic lateral sclerosis in Chinese subjects. **2021**, 14, 222	1

471	Chemical composition of (Forssk.) bunge and Desf. and evaluation of their multiple biological potentials. **2021**, 28, 6086-6096	9
470	Deciphering osteoarthritis genetics across 826,690 individuals from 9 populations. **2021**, 184, 4784-4818.e17	24
469	Exploring relationships between alcohol consumption, inflammation, and brain structure in a heavy drinking sample. **2021**, 45, 2256-2270	1
468	No evidence of neuronal damage as measured by neurofilament light chain in a HIV cure study utilising a kick-and-kill approach. **2021**, 7, 100056	
467	Potential Biomarkers Associated with Multiple Sclerosis Pathology. **2021**, 22,	2
466	Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children. **2021**, 8, 2013-2024	1
465	Serum NfL in spinocerebellar ataxia type 1 is increased already at the preataxic stage, correlating with proximity to clinical onset.	0
464	NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study. **2021**, 72, 103590	4
463	Evidence for and against subclinical disease activity and progressive disease in MOG antibody disease and neuromyelitis optica spectrum disorder. **2021**, 360, 577702	1
462	Design and evaluation of directional antenna for shoe-mounted sensor for position identification of elderly wanderer. **2021**, 34, 100451	0
461	Fluid Biomarkers of Frontotemporal Lobar Degeneration. **2021**, 1281, 123-139	1
460	Assessment of Neurofilament Light Protein as a Serum Biomarker in Rodent Models of Toxic-Induced Peripheral Neuropathy. **2021**, 267-275	
459	Minimal genetically encoded tags for fluorescent protein labeling in living neurons.	2
458	Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells. **2021**, 18, 363-378	14
457	Symptoms and Symptom Management in Survivorship Patients. **2021**, 145-202	0
456	NfL and pNfH are increased in Friedreich's ataxia. **2020**, 267, 1420-1430	9
455	Neurofilaments in progressive multiple sclerosis: a systematic review. **2021**, 268, 3212-3222	16
454	Cellular senescence in aging and age-related diseases: Implications for neurodegenerative diseases. **2020**, 155, 203-234	16

| 453 | Progressive supranuclear palsy: Advances in diagnosis and management. **2020**, 73, 105-116 | 17 |

| 452 | Neurofilament light chain in serum is significantly increased in chorea-acanthocytosis. **2020**, 80, 28-31 | 5 |

| 451 | Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective. **2020**, 19, 699-710 | 35 |

| 450 | Serum neurofilament light levels in normal aging and their association with morphologic brain changes. **2020**, 11, 812 | 118 |

| 449 | Serum neurofilament light in atrial fibrillation: clinical, neuroimaging and cognitive correlates. **2020**, 2, fcaa166 | 8 |

| 448 | Neurofilaments as blood biomarkers at the preataxic and ataxic stage of spinocerebellar ataxia type 3: a cross-species analysis in humans and mice. | 1 |

| 447 | Cerebral atherosclerosis contributes to Alzheimer's dementia independently of its hallmark amyloid and tau pathologies. | 3 |

| 446 | The conserved DNMT1 dependent methylation regions in human cells are vulnerable to environmental rotenone. | 1 |

| 445 | Serum Neurofilament Light in Patients with Frontotemporal Dementia Caused by CHMP2B Mutation. **2020**, 49, 533-538 | 4 |

| 444 | Combination of plasma amyloid beta and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. **2020**, 12, 118 | 54 |

| 443 | Reference values for plasma neurofilament light chain (NfL) in healthy Chinese. **2021**, 59, e153-e156 | 3 |

| 442 | [Evaluation of serum neurofilament light chains levels for diagnosis, treatment monitoring and prognosis in multiple sclerosis]. **2019**, 119, 7-13 | 1 |

| 441 | Genome-wide association study identifies CD1A associated with rate of increase in plasma neurofilament light in non-demented elders. **2019**, 11, 4521-4535 | 4 |

| 440 | Neurofilament light chain predicts risk of recurrence in cerebral amyloid angiopathy-related intracerebral hemorrhage. **2020**, 12, 23727-23738 | 6 |

| 439 | Serum neurofilament light chain rate of change in Alzheimer's disease: potentials applications and notes of caution. **2019**, 7, S133 | 4 |

| 438 | Biochemical Parameters in Cognitive Functions. **2020**, 16, 2479-2489 | 2 |

| 437 | National Institute of Neurological Disorders and Stroke: current funding status, opportunities, challenges, emerging scientific advances, and recommendations for neurosurgery. **2020**, 1-6 | 5 |

| 436 | What are we trying to prevent in Alzheimer disease?. **2019**, 21, 27-34 | 5 |

417	CHAPTER 6:Progressive Multiple Sclerosis: Drug Discovery. **2019**, 111-133	
416	CHAPTER 9:Emerging Drugs and Targets for Remyelination in Multiple Sclerosis. **2019**, 197-221	
415	White matter changes in the perforant path in patients with amyotrophic lateral sclerosis.	
414	Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis.	1
413	Serum neurofilament light as a prognostic marker for MS disability: Are we there yet?. **2020**, 94, 1013-1014	
412	Neural and glial damage markers in women after long-term weight-recovery from anorexia nervosa. **2022**, 135, 105576	0
411	Molecular mimicry of NMDA receptors may contribute to neuropsychiatric symptoms in severe COVID-19 cases. **2021**, 18, 245	9
410	Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis. **2021**, 24, 1534-1541	5
409	Body Mass Index and Allostatic Load are Directly Associated with Longitudinal Increase in Plasma Neurofilament Light Among Urban Middle-aged Adults. **2021**,	0
408	Neurofilament Light Chain Predicts Disease Severity and Progression in Multiple System Atrophy. **2021**,	1
407	The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis.. **2022**, 57, 103364	1
406	Neurodegenerative Disorders of Alzheimer, Parkinsonism, Amyotrophic Lateral Sclerosis and Multiple Sclerosis: An Early Diagnostic Approach for Precision Treatment. **2021**, 37, 67	3
405	The role of extracellular matrix phosphorylation on energy dissipation in bone. **2020**, 9,	2
404	Serum neurofilament light chain is not a useful biomarker of central nervous system involvement in women with Fabry disease. **2021**, 10, 276-282	
403	Longitudinal treatment responsiveness on plasma neurofilament light chain and glial fibrillary acidic protein levels in neuromyelitis optica spectrum disorder. **2021**, 14, 17562864211054952	3
402	Serum Neurofilament Light as a Biomarker of Traumatic Brain Injury in the Presence of Concomitant Peripheral Injury. **2021**, 16, 11772719211053449	1
401	Pediatric Multiple Sclerosis. **2020**, 37-66	
400	Functional characterization of Neurofilament Light b splicing andmisbalance in zebrafish.	

399	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum NfL and pNfH: A Longitudinal Multicentre Study. **2021**,	2
398	CSF Heavy Neurofilament May Discriminate and Predict Motor Neuron Diseases with Upper Motor Neuron Involvement. **2021**, 9,	
397	Alpha-Synuclein, cyclooxygenase-2 and prostaglandins-EP2 receptors as neuroinflammatory biomarkers of autism spectrum disorders: Use of combined ROC curves to increase their diagnostic values. **2021**, 20, 155	0
396	Serum neurofilament light as a biomarker for prognosis in patients with newly diagnosed Parkinson's disease.	
395	Association of Serum Neurofilament Light Levels With Long-term Brain Atrophy in Patients With a First Multiple Sclerosis Episode. **2020**, 3, e2016278	5
394	Reframing Alzheimer's Disease: Guided by a New Research Framework, the Field is Poised For Greater Precision and Promising Horizons. **2019**, 44, 282-289	
393	Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation. **2021**, 12, 715195	0
392	Neurofilament light chain as a biomarker for diagnosis of multiple sclerosis. **2021**, 20, 1308-1325	
391	Association Between Serum Levels of Neurofilament Light Chains and Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis. **2021**, 12, e00419	
390	Serum Levels of the Biomarkers Associated with Astrocytosis, Neurodegeneration, and Demyelination: Neurological Benefits of Citicoline Treatment of Patients with Ischemic Stroke and Atrial Fibrillation. **2021**, 53, 1-11	1
389	Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study. **2021**, 57, 103409	0
388	Association Between Serum Levels of Neurofilament Light Chains and Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis. **2021**, 12, e00419	0
387	Neurofilament Light Chain Protein Is a Predictive Biomarker for Stroke After Surgical Repair for Acute Type A Aortic Dissection. **2021**, 8, 754801	1
386	Serum neurofilament light chain in adult and pediatric patients with myelin oligodendrocyte glycoprotein antibody-associated disease: Correlation with relapses and seizures. **2021**,	0
385	Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives.. **2021**, 48674211058684	1
384	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. **2021**, 16, 79	0
383	Amyotrophic lateral sclerosis: Correlations between fluid biomarkers of NfL, TDP-43, and tau, and clinical characteristics. **2021**, 16, e0260323	4
382	White Matter Alterations in Spastic Paraplegia Type 5: A Multiparametric Structural MRI Study and Correlations with Biochemical Measurements. **2021**,	

381	Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. **2021**,	40
380	Clinical Biomarkers for Early Identification of Patients with Intracranial Metastatic Disease. **2021**, 13,	1
379	Serum Neurofilament Light Chain Levels and Myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Acquired Demyelinating Syndromes. **2021**, 12, 754518	1
378	Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. **2021**,	12
377	Cerebrospinal fluid neurofilament light predicts the rate of executive function decline in younger-onset dementia.. **2021**, 432, 120088	0
376	Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation. **2021**, 12, 715195	1
375	Fatigue in Patients With Multiple System Atrophy: A Prospective Cohort Study. **2021**,	1
374	CSF neurofilament light chain predicts 10-year clinical and radiologic worsening in multiple sclerosis.. **2021**, 7, 20552173211060337	2
373	CSF Neurofilament Light Chain Concentrations Predict Outcome in Bacterial Meningitis.. **2022**, 9,	1
372	Brain Volume Loss Can Occur at the Rate of Normal Aging in Patients with Multiple Sclerosis Who Are Free from Disease Activity.. **2022**, 11,	0
371	Short structural variants as informative genetic markers for ALS disease risk and progression.. **2022**, 20, 11	0
370	Functional brain activity constrained by structural connectivity reveals cohort-specific features for serum neurofilament light chain. **2022**, 2,	0
369	Higher Cerebrospinal Fluid Biomarkers of Neuronal Injury in Hiv-Associated Neurocognitive Impairment.	
368	Exploring Neurofilament Light Chain and Exosomes in the Genetic Forms of Frontotemporal Dementia.. **2022**, 16, 758182	0
367	Upregulated Retinal Neurofilament Expression in Experimental Optic Neuritis. 1-5	0
366	Cerebrospinal fluid neurofilament light chain differentiates behavioural variant frontotemporal dementia progressors from phenocopy non-progressors.	0
365	Neurofilament light chain as a disease severity biomarker in ATTRv: data from a single-centre experience.. **2022**, 43, 2845	1
364	Age-Adjusted Serum Neurofilament Predicts Cognitive Decline in Parkinson's Disease (MARK-PD).. **2022**,	1

363	Minimal genetically encoded tags for fluorescent protein labeling in living neurons.. **2022**, 13, 314	5
362	Serum neurofilament light chain and postural instability/gait difficulty (PIGD) subtypes of Parkinson's disease in the MARK-PD study.. **2022**, 1	0
361	Serum NFL discriminates Parkinson disease from essential tremor and reflect motor and cognition severity.. **2022**, 22, 39	0
360	Cerebrospinal fluid neurofilament light chain levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment. 10, 614	2
359	Changes in serum neurofilament light chain levels following narrowband ultraviolet B phototherapy in clinically isolated syndrome.. **2022**, e2494	1
358	Prospects for the use of graphene-based biological sensors in the early diagnosis of Alzheimer's disease (review of literature).. **2022**, 67, 5-12	
357	Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis.. **2022**, 375, 296-301	124
356	Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline.. **2022**,	2
355	Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings.. **2022**,	2
354	Levels of Serum Phosphorylated Neurofilament Heavy Subunit in Clinically Healthy Standardbred Horses.. **2021**, 110, 103861	1
353	Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damage.. **2022**, 105662	1
352	Serum Neurofilament Light Chain as a Biomarker of Brain Injury in Wilson's Disease: Clinical and Neuroradiological Correlations.. **2022**,	2
351	Detection of Neurofilament Light Chain with Label-Free Electrolyte-Gated Organic Field-Effect Transistors. 2102341	3
350	Prognosis and Diagnostic Biomarkers of Mild Traumatic Brain Injury: Current Status and Future Prospects.. **2022**,	0
349	An Age Dependent Mathematical Model of Neurofilament Trafficking in Healthy Conditions.. **2022**,	1
348	Protein tau concentration in blood increases after SCUBA diving: an observational study.. **2022**, 122, 993	0
347	Developing Biomarkers of Mild Traumatic Brain Injury: Promise and Progress of CNS-Derived Exosomes.. **2021**, 12, 698206	1
346	Neurofilament Light Chain as a Biomarker for Monitoring the Efficacy of Transcranial Magnetic Stimulation on Alcohol Use Disorder.. **2022**, 16, 831901	

345	Four Swedish cases of CSF1R-related leukoencephalopathy: Visualization of clinical phenotypes.. **2022**,	
344	Belayer: Modeling discrete and continuous spatial variation in gene expression from spatially resolved transcriptomics.	
343	Phosphorylated Neurofilament Heavy Chain: A Potential Diagnostic Biomarker in Amyotrophic Lateral Sclerosis.. **2022**,	0
342	The Neuroimmunology of Multiple Sclerosis: Fictions and Facts.. **2021**, 12, 796378	0
341	Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis.. **2022**,	1
340	A longitudinal investigation of blood neurofilament light chain levels in chronic cocaine users.	1
339	Blood GFAP as an emerging biomarker in brain and spinal cord disorders.. *Nature Reviews Neurology*, **2022**,	15 9
338	Type of serum collection tube does not impact neurofilament light chain levels.. **2022**, 59, 103676	0
337	Recent Advances in the Application Peptide and Peptoid in Diagnosis Biomarkers of Alzheimer's Disease in Blood.. **2021**, 14, 778955	0
336	Neurofilament light chain as a biological marker for amyotrophic lateral sclerosis: a meta-analysis study. **2021**, 1-12	0
335	Plasma and CSF NfL are differentially associated with biomarker evidence of neurodegeneration in a community-based sample of 70-year-olds.. **2022**, 14, e12295	0
334	OUP accepted manuscript.	1
333	[Prognostic markers of multiple sclerosis].. **2022**, 122, 22-27	
332	Autoantibodies targeting neuronal proteins as biomarkers for neurodegenerative diseases.. **2022**, 12, 3045-3056	2
331	Prediction of Disability in Multiple System Atrophy Based on Machine Learning Algorithm: A Prospective Cohort Study.	
330	Serum Creatine, Not Neurofilament Light, Is Elevated in CHCHD10-Linked Spinal Muscular Atrophy.. **2022**, 13, 793937	2
329	Characteristics of serum neurofilament light chain as a biomarker in hereditary spastic paraplegia type 4.. **2022**,	0
328	Serum neurofilament light chain, contactin-1 and complement activation in anti-MAG IgM paraprotein-related peripheral neuropathy.. **2022**, 1	1

327	Sleep quality: A common thread linking depression, post-traumatic stress, and post-concussive symptoms to biomarkers of neurodegeneration following traumatic brain injury.. **2022**, 1-11	2
326	Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis.. **2022**,	0
325	A map of neurofilament light chain species in brain and cerebrospinal fluid and alterations in Alzheimer's disease.. **2022**, 4, fcac045	2
324	A human tau seeded neuronal cell model recapitulates molecular responses associated with Alzheimer's disease.. **2022**, 12, 2673	0
323	Neurodegeneration and convergent factors contributing to the deterioration of the cytoskeleton in Alzheimer's disease, cerebral ischemia and multiple sclerosis (Review).. **2022**, 16, 27	1
322	Serum NfL and CHI3L1 for ALS and parkinsonian disorders in the process of diagnosis.. **2022**, 129, 301	
321	Deep Single-Cell-Type Proteome Profiling of Mouse Brain by Nonsurgical AAV-Mediated Proximity Labeling.. **2022**,	3
320	Plasma Amyloid Beta, Total-Tau and Neurofilament Light Chain Levels and the Risk of Stroke: A Prospective Population-Based Study.. **2022**,	2
319	The tail domain of neurofilament light chain accumulates in neuronal nuclei during oxidative injury.	
318	Moderne Diagnosestellung der Amyotrophen Lateralsklerose bin Update der Diagnosekriterien. **2022**, 53, 48-58	
317	Plasma neurofilament light chain as a biomarker for Fatal Familial Insomnia.. **2022**,	0
316	Update on Multiple Sclerosis Molecular Biomarkers to Monitor Treatment Effects.. **2022**, 12,	0
315	Nanomaterial-assisted microfluidics for multiplex assays.. **2022**, 189, 139	1
314	Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations.. **2022**, 23,	0
313	Development of an age-adjusted model for blood neurofilament light chain.. **2022**,	0
312	Evaluation of Neurofilament Light Chain as a Biomarker of Neurodegeneration in X-Linked Childhood Cerebral Adrenoleukodystrophy.. **2022**, 11,	1
311	Prediction and early biomarkers of cognitive decline in Parkinson disease and atypical parkinsonism: a population-based study.. **2022**, 4, fcac040	0
310	Serum neurofilament light levels are correlated to long-term neurocognitive outcome measures after cardiac arrest.. **2022**, 1-10	0

| 309 | Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.. **2022**, 21, 246-257 | 16 |

| 308 | Neurofilament light chain and retinal layers' determinants and association: A population-based study.. **2022**, | 1 |

| 307 | Neurofilament Light Chain Levels in Multiple Sclerosis Correlate With Lesions Containing Foamy Macrophages and With Acute Axonal Damage.. **2022**, 9, | 3 |

| 306 | The Added Value of Cerebrospinal Fluid Neurofilament Light Chain to Existing Diagnostic Methods and Biomarkers in a Mixed Memory Clinic Cohort of Consecutive Patients.. **2022**, 6, 121-127 | 0 |

| 305 | Association of Cerebrospinal Fluid Parameters and Neurofilament Light Chain With Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis.. **2022**, 13, 814734 | 0 |

| 304 | Serum and Cerebrospinal Fluid Biomarkers in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Associated Disease.. **2022**, 13, 866824 | 1 |

| 303 | Serum NfL in Alzheimer Dementia: Results of the Prospective Dementia Registry Austria.. **2022**, 58, | 0 |

| 302 | Anti-hypothalamus autoantibodies in anorexia nervosa: a possible new mechanism in neuro-physiological derangement?. **2022**, 1 | 1 |

| 301 | GABA Receptor-Stabilizing Protein Ubqln1 Affects Hyperexcitability and Epileptogenesis after Traumatic Brain Injury and in a Model of In Vitro Epilepsy in Mice.. **2022**, 23, | |

| 300 | Blood-Based Brain Injury Biomarkers to Prognosticate Outcome after Pediatric Cardiac Arrest. | |

| 299 | Biofluid Biomarkers of Alzheimer's Disease: Progress, Problems, and Perspectives.. **2022**, 1 | 1 |

| 298 | A One Medicine Mission for an Effective Rabies Therapy.. **2022**, 9, 867382 | |

| 297 | Development of Fluid Biomarkers for Alzheimer⯾ Disease. **2022**, 361-374 | |

| 296 | Blood-based biomarkers and traumatic brain injury-A clinical perspective.. **2022**, | 1 |

| 295 | Prospectively Assessing Serum Neurofilament Light Chain Levels As A Biomarker Of Paclitaxel-Induced Peripheral Neurotoxicity In Breast Cancer Patients.. **2022**, | 1 |

| 294 | CSF biomarkers for prion diseases.. **2022**, 105306 | 0 |

| 293 | Biomarkers in Moderate to Severe Pediatric Traumatic Brain Injury: A Review of the Literature.. **2022**, 130, 60-68 | |

| 292 | Neurofilament light chain and disease activity in patients with multiple sclerosis. **2021**, 22, 212-216 | |

291   Factors influencing serum neurofilament light chain levels in normal aging.. **2021**, 13,   2

290   Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes.. **2021**, 13, 199   2

289   Characteristics and Risk Factors of Persistent Neuropathic Pain in Recovered COVID-19 Patients.. **2021**,   4

288   Neurofilament markers in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. **2021**,   4

287   Neurofilament Light (NF-L) Chain Protein from a Highly Polymerized Structural Component of the Neuronal Cytoskeleton to a Neurodegenerative Disease Biomarker in the Periphery. **2021**, 7,   0

286   Correlation between cerebrospinal fluid and plasma neurofilament light protein in treated HIV infection: results from the COBRA study. **2021**, 1   0

285   Possible protective effects of CO Q10 against vincristine-induced peripheral neuropathy: Targeting oxidative stress, inflammation, and sarmoptosis.. **2021**, e22976   1

284   Clinical review of retinotopy. **2021**,

283   Absence of attack-independent neuroaxonal injury in MOG antibody-associated disease: Longitudinal assessment of serum neurofilament light chain.. **2021**, 13524585211063756   1

282   NT1-Tau Is Increased in CSF and Plasma of CJD Patients, and Correlates with Disease Progression.. **2021**, 10,   1

281   Blood-based biomarkers for Alzheimer's disease. **2021**, e14408   7

280   Increased risk of cognitive impairment and hyperglycemia-related mortality in late middle-aged African Americans with low serum adropin levels.

279   Altered protein secretion in Batten disease. **2021**, 14,   3

278   Associations of plasma neurofilament light chain and progranulin with frailty in older adults.. **2021**,   2

277   Treatment Challenges in Multiple Sclerosis - A Continued Role for Glatiramer Acetate?. **2022**, 13, 844873   0

276   Brain-derived neurotrophic factor protects serotonergic neurons against 3,4-methylenedioxymethamphetamine ("Ecstasy") induced cytoskeletal damage.. **2022**, 1   0

275   Plasma neurofilament light levels associate with muscle mass and strength in middle-aged and older adults: findings from GenoFit.. **2022**,   0

274   Blood-Based Biomarkers for Alzheimer's Disease Diagnosis and Progression: An Overview.. **2022**, 11,   0

273	Plasma Neurofilament Light Chain Levels Are Elevated in Children and Young Adults With Wolfram Syndrome.. **2022**, 16, 795317	0
272	Renal Function and Body Mass Index Contribute to Serum Neurofilament Light Chain Levels in Elderly Patients With Atrial Fibrillation.. **2022**, 16, 819010	1
271	SARS-CoV-2 and neurodegenerative diseases: what we know and what we don't.. **2022**, 1	7
270	Investigating the combination of plasma amyloid-beta and geroscience biomarkers on the incidence of clinically meaningful cognitive decline in older adults.. **2022**, 1	1
269	Table_1.XLSX. **2019**,	
268	Data_Sheet_1.PDF. **2019**,	
267	Blood biomarkers for Alzheimer's disease and related disorders.. **2022**,	2
266	Levels of Neurofilament Light at the Preataxic and Ataxic Stages of Spinocerebellar Ataxia Type 1.. **2022**,	0
265	Serum neurofilament light chain levels predict long-term disability progression in patients with progressive multiple sclerosis.. **2022**,	1
264	Relationship between cerebrospinal fluid neurodegeneration biomarkers and temporal brain atrophy in cognitively healthy older adults.. **2022**, 116, 80-91	2
263	A Literature Review of Traumatic Brain Injury Biomarkers.. **2022**,	2
262	Imaging Biomarkers for Alzheimer's Disease Using Magnetic Resonance Microscopy. **2022**, 283-314	
261	Lower cerebral arterial blood flow is associated with greater serum neurofilament light chain levels in multiple sclerosis patients.. **2022**,	0
260	How can we define the presymptomatic C9orf72 disease in 2022? An overview on the current definitions of preclinical and prodromal phases.. **2022**,	0
259	Neurofilament assessment in patients with cervical dystonia.. **2022**, 98, 70-71	1
258	Serum and cerebrospinal fluid phosphorylated neurofilament heavy subunit as a marker of neuroaxonal damage in tick-borne encephalitis.. **2022**, 103,	0
257	Serum-Based Biomarkers in Neurodegeneration and Multiple Sclerosis. **2022**, 10, 1077	1
256	The immunology of multiple sclerosis.. **2022**,	5

255	Investigation of Whole and Glandular Saliva as a Biomarker for Alzheimer's Disease Diagnosis. **2022**, 12, 595	1
254	Circulating neurofilament is linked with morbid obesity, renal function, and brain density.. **2022**, 12, 7841	0
253	Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia. **2022**, 14,	0
252	Temporal Patterning of Neurofilament Light as a Blood-Based Biomarker for Stroke: A Systematic Review and Meta-Analysis. **2022**, 13,	1
251	Transcriptional Profiling of Hippocampus Identifies Network Alterations in Alzheimer's Disease. **2022**, 12, 5035	
250	The analysis of dynamic gene expression patterns in peripheral blood of multiple sclerosis patients indicates possible diagnostic and prognostic biomarkers. **2022**, 147, 147-156	1
249	Plasma levels of S100B and neurofilament light chain protein in stress-related mental disorders.. **2022**, 12, 8339	0
248	Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma.. **2022**,	1
247	Combining biomarkers for prognostic modelling of Parkinson's disease.. **2022**,	1
246	Blood biomarkers of peripheral neuropathy.	2
245	Brain Biomarkers in Patients with COVID-19 and Neurological Manifestations: A Narrative Review. **2022**, 09, 010-015	
244	Focus on the Role of the NLRP3 Inflammasome in Multiple Sclerosis: Pathogenesis, Diagnosis, and Therapeutics. **2022**, 15,	1
243	Neuroinflammation in HIV-associated depression: evidence and future perspectives.	2
242	Biomarkers of Tuberculous Meningitis and Pediatric Human Immunodeficiency Virus on the African Continent. 13,	
241	Neuronal and Neuroaxonal Damage Cerebrospinal Fluid Biomarkers in Autoimmune Encephalitis Associated or Not with the Presence of Tumor. **2022**, 10, 1262	1
240	Baseline Neurofilament Levels in Cerebrospinal Fluid Do Not Correlate with Long-term Prognosis in Multiple Sclerosis. **2022**, 103940	
239	Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis. 1352458522109072	
238	A new generation of AD biomarkers: 2019 to 2021. **2022**, 79, 101654	1

237	A Method to Combine Neurofilament Light Measurements From Blood Serum and Plasma in Clinical and Population-Based Studies. 13,	0
236	Fluid phase biomarkers in multiple sclerosis. **2022**, 35, 286-292	0
235	New biomarker paves the way for a clinical trial for neurodegeneration in Langerhans cell histiocytosis.	
234	Higher cerebrospinal fluid biomarkers of neuronal injury in HIV-associated neurocognitive impairment.	0
233	Neurofilament light chain: a new marker for neuronal decay in the anterior chamber fluid of patients with glaucoma. bjophthalmol-2021-320828	1
232	Plasma neurofilament light chain levels suggest neuroaxonal stability following therapeutic remyelination in people with multiple sclerosis. jnnp-2022-329221	1
231	Linking Plasma Amyloid Beta and Neurofilament Light Chain to Intracortical Myelin Content in Cognitively Normal Older Adults. 14,	0
230	Plasma Neurofilament Light Chain Is Associated with Cognitive Impairment after Posterior Circulation Stroke. **2022**, 2022, 1-7	
229	Pathophysiology of neurodegenerative diseases: An interplay among axonal transport failure, oxidative stress, and inflammation?. **2022**, 101628	1
228	A Novel Neurofilament Light Chain ELISA Validated in Patients with Alzheimers Disease, Frontotemporal Dementia, and Subjective Cognitive Decline, and the Evaluation of Candidate Proteins for Immunoassay Calibration. **2022**, 23, 7221	0
227	Distribution of five clinically important neuroglial proteins in the human brain. **2022**, 15,	2
226	Biological Brain Age Prediction Using Machine Learning on Structural Neuroimaging Data: Multi-Cohort Validation Against Biomarkers of Alzheimers Disease and Neurodegeneration stratified by sex.	
225	Serum Neurofilament Light Chain in Patients With Atrial Fibrillation.	1
224	Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers.	0
223	Multi-Omics Interdisciplinary Research Integration to Accelerate Dementia Biomarker Development (MIRIADE). 13,	0
222	Neurofilament Light Chain: A Candidate Biomarker of Perioperative Stroke. 14,	0
221	The physio-affective phenome of major depression is strongly associated with biomarkers of astroglial and neuronal projection toxicity which in turn are associated with peripheral inflammation, insulin resistance and lowered calcium.	0
220	Serum neurofilament light chain levels in Covid-19 patients without major neurological manifestations.	2

219 Case Report: A 72-Year-Old Woman With Progressive Motor Weakness, Dry Eyes and High Levels of Serum Neurofilament Light Chain. 13,

218 Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5-90 years. 2

217 Effects of antidiabetic agents on Alzheimer's disease biomarkers in experimentally induced hyperglycemic rat model by streptozocin. **2022**, 17, e0271138

216 Clinical utility of fluid biomarkers in the evaluation of cognitive impairment: a systematic review and meta-analysis.

215 Contributors to Serum NfL Levels in People without Neurologic Disease. 0

214 Ubiquitin carboxyl-terminal esterase L1 is not elevated in the serum of concussed rugby players: an observational cross-sectional study. **2022**, 12,

213 Consensus on early detection of disease progression in patients with multiple sclerosis. 13, 0

212 Modulatory effects of vitamin B3 and its derivative on the levels of apoptotic and vascular regulators and cytoskeletal proteins in diabetic rat brain as signs of neuroprotection. **2022**, 130207

211 Neurofilament light increases over time in severe COVID-19 and is associated with delirium. 0

210 Inflammation Disrupts Cognitive Integrity via Plasma Neurofilament Light Chain Coupling Brain Networks in Alzheimer's Disease. **2022**, 1-14

209 Mice in translational neuroscience: What R we doing?. **2022**, 217, 102330 3

208 Differential diagnosis of demyelinating diseases: what's new?. **2022**, 80, 137-142

207 Neurofilament light levels predict clinical progression and death in multiple system atrophy. 0

206 Multidimensional overview of neurofilament light chain contribution to comprehensively understanding multiple sclerosis. 13,

205 otential Laboratory Markers of Vincristine-Induced Peripheral Neuropathy. **2022**, 77, 208-213

204 Association of Cerebrospinal Fluid Neurofilament Heavy Protein Levels With Clinical Progression in Patients With Parkinson Disease. **2022**, 5, e2223821

203 Neurospecific Molecules Measured in Periphery in Humans: How Do They Correlate with the Brain Levels? A Systematic Review. **2022**, 23, 9193 1

202 Cortical distribution of neurofilaments associates with pathological hallmarks and MRI measures of atrophy and diffusivity in Parkinson's disease.

201	Central nervous system biomarkers GFAp and NfL associate with post-acute cognitive impairment and fatigue following critical COVID-19.	
200	New quantification method for monitoring 18 l -amino acids levels in schizophrenic patients by high-performance liquid chromatography coupled to tandem quadrupole mass spectrometer.	
199	Neuro-Axonal Damage and Alteration of Blood Brain Barrier Integrity in COVID-19 Patients. **2022**, 11, 2480	1
198	Neurochemical Monitoring of Traumatic Brain Injury by the Combined Analysis of Plasma Beta-Synuclein, NfL, and GFAP in Polytraumatized Patients. **2022**, 23, 9639	
197	Association of Serum GFAP with Functional and Neurocognitive Outcome in Sporadic Small Vessel Disease. **2022**, 10, 1869	0
196	Neurons: The Interplay between Cytoskeleton, Ion Channels/Transporters and Mitochondria. **2022**, 11, 2499	1
195	Quantitative susceptibility mapping and blood neurofilament light chain differentiate between parkinsonian disorders. 14,	0
194	Plasma neurofilament light chain in Chinese children with later-onset spinal muscular atrophy. **2022**, 60, e237-e239	
193	The 2022 Lady Estelle Wolfson Lectureship on Neurofilaments.	0
192	Neurofilament light chain and S100B serum levels are associated with disease severity and outcome in patients with aneurysmal subarachnoid hemorrhage. 13,	0
191	Proteomic Markers and Early Prediction of Alzheimer Disease. **2022**, 87, 762-776	
190	Different AT(N) profiles and clinical progression classified by two different N markers using total tau and neurofilament light chain in cerebrospinal fluid. **2022**, 4, e000321	0
189	Neurofilament light chain in central nervous system infections: a prospective study of diagnostic accuracy. **2022**, 12,	
188	The New Biomarker in Town: Neurofilament Light Chain. **2022**, 137, A15-A15	
187	Analysis of Clinical Features, Diagnostic Tests, and Biomarkers in Patients With Suspected Creutzfeldt-Jakob Disease, 2014-2021. **2022**, 5, e2225098	1
186	Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register. 135245852211140	1
185	Human microRNA-4433 (hsa-miR-4443) Targets 18 Genes to be a Risk Factor of Neurodegenerative Diseases. **2022**, 19,	1
184	Size-adjustable self-assembled nanoparticles through microfluidic platform promotes neuronal differentiation of mouse embryonic stem cells. **2022**, 140, 213056	1

183	Calcium silicate nanowires-containing multicellular bioinks for 3D bioprinting of neural-bone constructs. **2022**, 46, 101584	2
182	Neurofilaments in neurologic disorders and beyond. **2022**, 441, 120380	
181	Dynamics of Inflammatory and Neurodegenerative Biomarkers after Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. **2022**, 23, 10946	1
180	Association of Blood-Based Brain Injury Biomarker Concentrations With Outcomes After Pediatric Cardiac Arrest. **2022**, 5, e2230518	0
179	Adaptive structural changes in the motor cortex and white matter in Parkinson's disease.	0
178	The multifaceted role of neurofilament light chain protein in non-primary neurological diseases.	0
177	Plasma neurofilament light chain (NfL) reference interval determination in an Age-stratified cognitively unimpaired cohort. **2022**, 535, 153-156	0
176	A novel photoelectrochemical microfluidic chip for multi-index determination of diabetes and its complications. **2022**, 217, 114719	0
175	Increased levels of neurofilament light chain in suicide attempters' serum. **2022**, 13, 218-223	0
174	Post-translational Modifications in Brain Diseases: A Future for Biomarkers. **2022**, 129-141	0
173	White matter alterations in chronic MDMA use: Evidence from diffusion tensor imaging and neurofilament light chain blood levels. **2022**, 36, 103191	0
172	Future directions. **2023**, 175-209	0
171	The Brave New World of Early Treatment of Multiple Sclerosis: Using the Molecular Biomarkers CXCL13 and Neurofilament Light to Optimize Immunotherapy. **2022**, 10, 2099	0
170	Uman Type NF-L Antibodies Are Effective Reagents for the Imaging of Neurodegeneration.	0
169	Serum neurofilament light chain and initial severity of neurological disease predict the early neurological deterioration in Wilson's disease.	0
168	Serum Neurofilament Light in Neurosyphilis: A Pilot Study. Publish Ahead of Print,	0
167	Altered Immune Response to the Epstein-Barr Virus as a Prerequisite for Multiple Sclerosis. **2022**, 11, 2757	0
166	Biomarkers involved in the pathogenesis of cerebral small-vessel disease. 13,	0

165	Serum glial fibrillary acidic protein and neurofilament light chain in patients with early treated phenylketonuria. 13,	0
164	Neurofilament-light chain quantification by SimoaTM and EllaTM in plasma from patients with dementia: a comparative study.	0
163	Improve the Protein Complex Prediction with Protein Language Models.	0
162	Neurofilament light as a biomarker for motor decline in Parkinson's disease. 16,	0
161	Assessment of Pretreatment and Posttreatment Evolution of Neurofilament Light Chain Levels in Patients Who Develop Immune Effector Cell‑Associated Neurotoxicity Syndrome.	0
160	LPS-Induced Coagulation and Neuronal Damage in a Mice Model Is Attenuated by Enoxaparin. **2022**, 23, 10472	0
159	Dracaena cochinchinensis stemwood extracts inhibit amyloid-β fibril formation and promote neuronal cell differentiation. 13,	0
158	Brain neuronal and glial damage during acute COVID-19 infection in absence of clinical neurological manifestations. jnnp-2022-329933	0
157	Association of admission serum levels of neurofilament light chain and in-hospital mortality in geriatric patients with COVID-19.	1
156	Starting signal: Aberrant kinase activation as a trigger for SARS-CoV-2 induced axonal damage. 2,	0
155	Effects of short-term unloading and active recovery on human motor unit properties, neuromuscular junction transmission and transcriptomic profile.	2
154	Point-of-care electrochemical testing of biomarkers involved in inflammatory and inflammatory-associated medical conditions.	0
153	Neurofilament light chain in blood as a diagnostic and predictive biomarker for multiple sclerosis: A systematic review and meta-analysis. **2022**, 17, e0274565	0
152	Sustained Increase in Serum Glial Fibrillary Acidic Protein after First ST-Elevation Myocardial Infarction. **2022**, 23, 10304	2
151	Diagnosis and classification of optic neuritis. **2022**,	3
150	Diabetes mellitus is associated with higher serum neurofilament light chain levels in the general U.S. population.	0
149	Neurofilament light chain and vaccination status associate with clinical outcomes in severe COVID-19. **2022**, 105272	1
148	Age- and disease-specific reference values for neurofilament light presented in an online interactive support interface.	1

147	Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy. **2022**, 14,	0
146	Neurodegeneration Markers in the Cerebrospinal Fluid of 100 Patients with Schizophrenia Spectrum Disorder.	0
145	Cerebrospinal fluid neurofilament light chain differentiates behavioural variant frontotemporal dementia progressors from non-progressors. **2022**, 442, 120439	0
144	Amyotrophic Lateral Sclerosis: Neurochemical Biomarkers. **2022**, 295-310	0
143	4-hydroxyisoleucine mediated IGF-1/GLP-1 signalling activation prevents propionic acid-induced autism-like behavioural phenotypes and neurochemical defects in experimental rats. **2022**, 102296	0
142	Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease.	0
141	Neurological symptoms and neuronal damage markers in acute COVID-19: Is there a correlation? A pilot study.	0
140	Classification accuracy of blood-based and neurophysiological markers in the differential diagnosis of Alzheimer's disease and frontotemporal lobar degeneration. **2022**, 14,	0
139	Dementia with Lewy bodies: Impact of co-pathologies and implications for clinical trial design.	1
138	Neurofilament Light Chain Levels Are Predictive of Clinical Conversion in Radiologically Isolated Syndrome. **2023**, 10, e200044	0
137	Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model. **2022**, 19,	0
136	Prognostic Markers in Multiple Sclerosis.	0
135	Belayer: Modeling discrete and continuous spatial variation in gene expression from spatially resolved transcriptomics. **2022**, 13, 786-797.e13	0
134	The Clinical Application of Optimized AT(N) Classification in Alzheimer's Clinical Syndrome (ACS) and non-ACS Conditions.	0
133	Patient's perspective in clinical practice to assess and predict disability in multiple sclerosis. **2022**, 12,	0
132	Cerebrospinal fluid neurofilament light chain as a potential prognostic biomarker for leptomeningeal metastasis. **2022**, 24,	0
131	Cerebrospinal fluid neurofilament light and cerebral atrophy in younger-onset dementia and primary psychiatric disorders.	0
130	Ella versus Simoa Serum Neurofilament Assessment to Monitor Treatment Response in Highly Active Multiple Sclerosis Patients. **2022**, 23, 12361	1

129	Plasma neurofilament light as blood marker for poor brain white matter integrity among middle-aged urban adults. **2022**,	o
128	Microbial dysbiosis in the gut drives systemic autoimmune diseases. 13,	3
127	Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers.	o
126	An innovative approach for the evaluation of prolonged disorders of consciousness using NF-L and GFAP biomarkers: a pivotal study. **2022**, 12,	1
125	Neurofilaments contribution in clinic: state of the art. 14,	o
124	Plasma P-Tau181 and Neuropsychiatric Symptoms in Preclinical and Prodromal Alzheimer Disease. 10.1212/WNL.0000000	1
123	Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review.	o
122	Physical Activity and Rising Neurofilament Light Chain in Genetic Frontotemporal DegenerationDiagnosis Is Not Destiny.	o
121	Serum neurofilament light levels in natalizumab-treated patients with multiple sclerosis who switch to extended interval dosing from every-4-week dosing in real-world clinical practice. 135245852211309	o
120	TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4. **2022**,	1
119	Evaluation of cerebrospinal fluid UCH-L1, GFAP, and NF-L as novel markers for the diagnosis of neurosyphilis among HIV-negative patients. **2022**,	o
118	Neurofilament light chain: a promising diagnostic biomarker for functional motor disorders.	o
117	Plasma Neurofilament Light Chain Predicts Mortality and Long-Term Neurological Outcomes in Patients with Intracerebral Hemorrhage. **2022**, 0	o
116	Multiple sclerosis progression: time for a new mechanism-driven framework. **2022**,	o
115	Comparative analysis of neurofilament light chain levels in the serum and cerebrospinal fluid in rats subjected to partial sciatic nerve ligation. **2022**,	o
114	Plasma neurofilament light chain in memory clinic practice: Evidence from a real-life study. **2023**, 176, 105937	o
113	Blood Biomarkers for the Diagnosis of Neurodegenerative Dementia: A Systematic Review. 089198872211416	o
112	Cerebrospinal fluid quinolinic acid is strongly associated with delirium and mortality in hip fracture patients.	1

111	Real-Life Experience of the Effects of Cladribine Tablets on Lymphocyte Subsets and Serum Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis Patients. **2022**, 12, 1595	1
110	Associations of sNfL with clinico-radiological measures in a large MS population.	0
109	Visinin-like protein 1 levels in blood and CSF as emerging markers for Alzheimer's and other neurodegenerative diseases. **2022**, 14,	0
108	Cerebrospinal fluid biomarkers in SARS-CoV-2 patients with acute neurological syndromes. **2022**,	0
107	Serum Neurofilament Identifies Patients With Multiple Sclerosis With Severe Focal Axonal Damage in a 6-Year Longitudinal Cohort. **2023**, 10, e200055	0
106	Perioperative ischaemic brain injury and plasma neurofilament light: a secondary analysis of two prospective cohort studies. **2022**,	0
105	Vitamin E depletion is associated with subclinical axonal degeneration in juvenile horses.	0
104	A pediatric quantitative systems pharmacology model of neurofilament trafficking in spinal muscular atrophy treated with the antisense oligonucleotide nusinersen.	0
103	Neurofilament Light Chain in Cerebrospinal Fluid as a Novel Biomarker in Evaluating Both Clinical Severity and Therapeutic Response in Niemann-Pick Disease, Type C1. **2022**,	0
102	Genome-wide Association Study Meta-analysis of Neurofilament light (NfL) levels in blood reveals novel loci related to neurodegeneration.	0
101	Cerebrospinal fluid neurofilament dynamic profiles predict cognitive progression in individuals with de novo Parkinson's disease. 14,	0
100	Association of neurofilament light chain with renal function: mechanisms and clinical implications. **2022**, 14,	0
99	Neurofilament light chain levels predict encephalopathy and outcome in community-acquired pneumonia.	0
98	Neurological Complications of Conventional and Novel Anticancer Treatments. **2022**, 14, 6088	0
97	Association of Serum Neurofilament Light Chain with Depressive Symptoms: a population-based study.	0
96	Aligning payer and provider strategies with the latest evidence to optimize clinical outcomes for patients with neuromyelitis optica spectrum disorder. **2022**, 28, S3-S27	0
95	Axonal degeneration in the anterior insular cortex is associated with Alzheimer's co-pathology in Parkinson's disease and dementia with Lewy bodies. **2022**, 11,	0
94	Diagnostic challenges for dementia in Australia: are blood-based biomarkers the solution?. **2022**, 52, 2181-2185	0

93	Role of Tau in Various Tauopathies, Treatment Approaches, and Emerging Role of Nanotechnology in Neurodegenerative Disorders.	0
92	Validity of serum neurofilament light chain as a prognostic biomarker of disease activity in multiple sclerosis.	0
91	Neurofilament Light Chain and Dorsal Root Ganglia Injury After Adeno-Associated Virus 9 Gene Therapy in Nonhuman Primates. **2022**,	0
90	Plasma Neurofilament Light Chain (NF-L) Is a Prognostic Biomarker for Cortical Damage Evolution but Not for Cognitive Impairment or Epileptogenesis Following Experimental TBI. **2022**, 23, 15208	2
89	Neuronal Cytoskeleton and HIV-Mediated Neurodegeneration. **2022**, 2043-2058	0
88	Elevated neurofilament light chain CSF/serum ratio indicates impaired CSF outflow in idiopathic intracranial hypertension. **2023**, 20,	0
87	Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial. 135245852211447	1
86	Subtle Differences in Cognition in 70-Year-Olds with Elevated Cerebrospinal Fluid Neurofilament Light and Neurogranin: A H70 Cross-Sectional Study. **2023**, 91, 291-303	0
85	Serum neurofilament light chain in myasthenia gravis subgroups: An exploratory cohort and case⬜control study. 13,	0
84	NMN: The NAD Precursor at the Intersection Between Axon Degeneration and Anti-ageing Therapies. **2023**,	0
83	Cerebrospinal fluid proteomics indicates immune dysregulation and neuronal dysfunction in antibody associated autoimmune encephalitis. **2023**, 135, 102985	0
82	Brain-derived neurotrophic factor, neurofilament light and glial fibrillary acidic protein do not change in response to aerobic training in people with MS-related fatigue ⬜a secondary analysis of a randomized controlled trial. **2023**, 70, 104489	0
81	Molecular biomarkers and cognitive impairment in multiple sclerosis: State of the field, limitations, and future direction ⬜A systematic review and meta-analysis. **2023**, 146, 105035	0
80	Types and Concentrations of Blood-Based Biomarkers in Adults With Peripheral Neuropathies. **2022**, 5, e2248593	0
79	Novel CSF Biomarkers Tracking Autoimmune Inflammatory and Neurodegenerative Aspects of CNS Diseases. **2023**, 13, 73	0
78	Detection of Alzheimer's Disease Biomarker using Anti-NFL Antibody Conjugated Gold Nanoparticles. **2022**, 37, 123-130	0
77	PARIN5, a Novel Thrombin Receptor Antagonist Modulates a Streptozotocin Mice Model for Diabetic Encephalopathy. **2023**, 24, 2021	0
76	Neurofilament light chain marks severity of papilledema in idiopathic intracranial hypertension.	0

75   Serum neurofilament light chain in functionally relevant coronary artery disease and adverse cardiovascular outcomes. 1-22   o

74   Pre-analytical long-term stability of neopterin and neurofilament light in stored cerebrospinal fluid samples. **2023**,   o

73   Bacillus amyloliquifaciens-Supplemented Camel Milk Suppresses Neuroinflammation of Autoimmune Encephalomyelitis in a Mouse Model by Regulating Inflammatory Markers. **2023**, 15, 550   o

72   Nutritional supplement and dietary interventions as a prophylaxis or treatment of sub-concussive repetitive head impact (SRHI) and mild traumatic brain injury (mTBI): A systematic review.   o

71   The updated development of blood-based biomarkers for Huntington's disease.   o

70   Effects of a 2-year exercise training on neuromuscular system health in older individuals with low muscle function.   o

69   Focused Ultrasound-mediated Liquid Biopsy in a Tauopathy Mouse Model.   o

68   Neurofilament light chain is increased in the parahippocampal cortex and associates with pathological hallmarks in Parkinson's disease dementia. **2023**, 12,   o

67   Biomarkers in Brain Traumatic Injury. **2022**, 11, 133-153   o

66   Evolving markers in amyotrophic lateral sclerosis. **2023**,   o

65   Peripheral Biomarkers in Manifest and Premanifest Huntington's Disease. **2023**, 24, 6051   o

64   Progress in blood biomarkers of subjective cognitive decline in preclinical Alzheimer's disease. **2023**, 136, 505-521   o

63   Validation of ELISA assays for the calculation of FLC indices for the diagnosis of intrathecal immunoglobulin synthesis. **2023**,   o

62   Serum neurofilament light chain cut-off definition for clinical diagnosis and prognosis of amyotrophic lateral sclerosis..   o

61   Serum neurofilament light chain in LRRK2 related Parkinson's disease: A five years follow-up. **2023**, 110, 12-18   o

60   Changes in neurofilament light chain protein (NEFL) in children and adolescents with Schizophrenia and Bipolar Disorder: Early period neurodegeneration. **2023**, 161, 342-347   o

59   Fluid biomarkers for the diagnosis of neurodegenerative diseases. **2023**, 8, 100062   o

58   Immunocal® limits gliosis in mouse models of repetitive mild-moderate traumatic brain injury. **2023**, 1808, 148338   o

57	The physio-affective phenome of major depression is strongly associated with biomarkers of astroglial and neuronal projection toxicity which in turn are associated with peripheral inflammation, insulin resistance and lowered calcium. **2023**, 331, 300-312	0
56	Tr1 cell-mediated protection against autoimmune disease by intranasal administration of a fusion protein targeting cDC1 cells.	0
55	Prediction of early-wheelchair dependence in multiple system atrophy based on machine learning algorithm: A prospective cohort study. **2023**, 8, 100183	0
54	Associations between multiple heavy metals exposure and neural damage biomarkers in welders: A cross-sectional study. **2023**, 869, 161812	0
53	Brain-specific biomarkers: on the winding path to accessibility and clinical relevance. **2023**, 30, 804-805	0
52	Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Potential Diagnostic Biomarkers in Autism Spectrum Disorders: A Preliminary Study. **2023**, 24, 3057	0
51	Editorial: Advanced computational systems biology approaches for accelerating comprehensive research of the human brain. 14,	0
50	EpsteinBarr virus as a leading cause of multiple sclerosis: mechanisms and implications. **2023**, 19, 160-171	2
49	High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis. **2023**, 30, 1389-1399	0
48	TDP-43 Proteinopathy Specific Biomarker Development. **2023**, 12, 597	0
47	Magnetic transferrin nanoparticles (MTNs) assay as a novel isolation approach for exosomal biomarkers in neurological diseases. **2023**, 27,	0
46	The role of serum brain injury biomarkers in individuals with a mild-to-moderate COVID infection and Long-COVID - results from the prospective population-based COVI-GAPP study.	0
45	Hallmarks of neurodegenerative diseases. **2023**, 186, 693-714	1
44	Serum Neurofilament Light Chain as Biomarker for Cladribine-Treated Multiple Sclerosis Patients in a Real-World Setting. **2023**, 24, 4067	0
43	Cerebrospinal Fluid and Blood Biomarkers in Patients with Post-Traumatic Disorders of Consciousness: A Scoping Review. **2023**, 13, 364	0
42	O-GlcNAcylation regulates neurofilament-light assembly and function and is perturbed by Charcot-Marie-Tooth disease mutations.	0
41	Current State and Future Directions in the Diagnosis of Amyotrophic Lateral Sclerosis. **2023**, 12, 736	0
40	Probiotic-Fermented Camel Milk Attenuates Neurodegenerative Symptoms via SOX5/miR-218 Axis Orchestration in Mouse Models. **2023**, 16, 357	0

| 39 | Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer's Disease. | 0 |

38 — Effect of long-term antihypertensive treatment on cerebrovascular structure and function in hypertensive rats. **2023**, 13, — 0

37 — From CoNFLict to Confidence: Solving a Diagnostic Dilemma Using Neurofilament Light – A Case Report. — 0

36 — Neurofilament light chain as neuronal injury marker – what is needed to facilitate implementation in clinical laboratory practice?. **2023**, — 0

35 — Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy. **2023**, 615, 668-677 — 0

34 — Evidence of polygenic regulation of the physiological presence of neurofilament light chain in human serum. 14, — 0

33 — Serum neurofilament light chain levels are associated with early neurological deterioration in minor ischemic stroke. 14, — 0

32 — Neurofilament-light chain quantification by Simoa and Ella in plasma from patients with dementia: a comparative study. **2023**, 13, — 0

31 — Circulating Brain-Injury Markers After Surgery for Craniosynostosis. **2023**, — 0

30 — An eye to the future: Acute and long-term neuro-ophthalmological and neurological complications of COVID-19. — 0

29 — Recent advances in DNA-based electrogenerated chemiluminescence biosensors. — 0

28 — The clinical application of optimized AT(N) classification in Alzheimer's clinical syndrome (ACS) and non-ACS conditions. **2023**, 127, 23-32 — 0

27 — Brain Changes in Diabetes and Cognitive Dysfunction. **2023**, 381-395 — 0

26 — Alteration of neurofilament heavy chain and its phosphoforms reveals early subcellular damage beyond the optic nerve head in glaucoma. 14, — 0

25 — Serum glial fibrillary acidic protein and neurofilament light chain as biomarkers of retinal neurodysfunction in early diabetic retinopathy: results of the EUROCONDOR study. — 0

24 — Serum neurofilament light concentrations are associated with cortical thinning in anorexia nervosa. 1-9 — 0

23 — A Multiple-Responsive Fluorescence Probe Based on Water-Soluble Fluorescent Conjugated Polymer for Biomolecules Detection. **2023**, 5, 2877-2886 — 0

22 — Challenges of the Effectiveness of Traumatic Brain Injuries Biomarkers in the Sports-Related Context. **2023**, 12, 2563 — 0

21	Cognitive Intervention Effects Vary as a Function of Plasma Neurofilament Light Chain Levels: A PICMOR Randomized Controlled Trial.	0
20	A Longitudinal Investigation of Blood Neurofilament Light Chain Levels in Chronic Cocaine Users.	0
19	Serum proteins for monitoring and predicting visual function in patients with recent optic neuritis. **2023**, 13,	0
18	Serum metabolic signatures for Alzheimer's Disease reveal alterations in amino acid composition and energy metabolism A validation study.	0
17	Biomarkers in autoimmune diseases of the central nervous system. 14,	0
16	A global view of the genetic basis of Alzheimer disease.	0
15	Artificial intelligence in precision medicine. **2023**, 531-569	0
14	A detection model for cognitive dysfunction based on volatile organic compounds from a large Chinese community cohort.	0
13	The association between inflammatory markers in blood and cerebrospinal fluid: a systematic review and meta-analysis.	0
12	Myelin Oligodendrocyte Glycoprotein as an Autoantigen in Inflammatory Demyelinating Diseases of the Central Nervous System. **2023**, 88, 551-563	0
11	Blood neurofilament light chain in Parkinson's disease.	0
10	Biological brain age prediction using machine learning on structural neuroimaging data: multi-cohort validation against biomarkers of Alzheimer's disease and neurodegeneration stratified by sex. 12,	0
9	Hotly anticipated ALS drug could pave way for more brain treatments.	0
8	Biofluid Biomarkers in the Prognosis of Amyotrophic Lateral Sclerosis: Recent Developments and Therapeutic Applications. **2023**, 12, 1180	0
7	Biomarkers of Alzheimer's Disease: Past, Present and Future Clinical Use. **2023**, 100063	0
6	Gamma neuromodulation improves episodic memory and its associated network in amnestic mild cognitive impairment: A pilot study. **2023**,	0
5	Serum neurofilament light chain levels are associated with all-cause mortality in the general US population.	0
4	Blood Based Biomarkers of Central Nervous System Involvement in Wilson's Disease. **2023**, 13, 1554	0

3	Network connectivity and local transcriptomic vulnerability underpin cortical atrophy progression in Parkinson's disease.	0
2	Application Value of Serum Neurofilament Light Protein for Disease Staging in Huntington's Disease.	0
1	Serum Neurofilament light chain (NfL) levels in children with and without neurologic diseases. **2023** ,	0